Stereotactic body radiotherapy versus conventional/moderate fractionated radiation therapy with androgen deprivation therapy for unfavorable risk prostate cancer

Table 2 Multivariable overall survival (OS) analysis between SBRT+ADT versus EBRT+ADT (referent) in overall cohort and select subgroups for unfavorable intermediate (a) and high (b) risk prostate cancer

	HR	95% CI	p
a. Unfavorable Intermediate Risk
Overall	1.09	0.68–1.74	.72
Subgroup Analyses
Excluding any SBRT < 7 Gy per fraction	1.15	0.72–1.83	.57
Excluding any EBRT < 2 Gy per fraction and < 74 Gy total dose	1.24	0.79–1.96	.35
Excluding Charlson Deyo ≥1	1.29	0.89–1.34	.33
Excluding age ≥ 65	1.13	0.86–1.36	.60
b. High Risk
Overall	0.93	0.76–1.14	.51
Subgroup Analyses
Excluding SBRT if < 7 Gy per fraction	0.92	0.74–1.14	.44
Excluding EBRT if < 2 Gy per fraction and < 74 Gy total dose	0.90	0.74–1.10	.30
Excluding Charlson Deyo ≥1	0.83	0.66–1.03	.10
Excluding age ≥ 65	0.72	0.44–1.17	.18

ISSN: 1748-717X